There is no evidence of an increased risk for major adverse cardiovascular events (MACE) after vaccination with BNT162b2 or CoronaVac in patients with cardiovascular disease (CVD).
Moderna Inc. announced that the revamped COVID-19 booster shot it has developed to fight omicron and its subvariants should be ready for public use by August.
World Trade Center (WTC) responders who suffer from exposure-related chronic conditions also face an increased risk for worse COVID-19 outcomes, including long COVID.
A US Centers for Disease Control and Prevention vaccine advisory panel voted to recommend that Americans 65 years and older get the new, more potent flu shots because the regular shot does not offer enough protection.
The inability to successfully complete the 10-second, one-legged stance in middle age is independently associated with premature all-cause mortality.
Wearable sensor technology could facilitate detection of presymptomatic COVID-19.
Final evidence from the WHO Solidarity clinical trials shows that remdesivir has only a slight protective effect and only among certain patients with COVID-19.
There are sex-related differences in COVID-19 sequelae and long COVID-19 syndrome.
Only one-third of individuals with neurologic symptoms following acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection report complete symptom resolution by six months.
The United States is deploying an enhanced nationwide vaccination strategy to counter the continuing spread of monkeypox, federal public health officials announced at a White House briefing.
